LYZ Antibody

What is lysozyme (LYZ) and why is it important in research?

Lysozyme (LYZ) is a 17 kDa antimicrobial enzyme that catalyzes the hydrolysis of bacterial cell wall peptidoglycan by cleaving the β(1-4) glycosidic linkages between N-acetylmuramic acid and N-acetylglucosamine . It serves as a key player in the body's defense against bacterial infections by breaking down bacterial cell walls and preventing their growth .

Beyond its antimicrobial activity, LYZ:

• Functions in both hydrolysis and transglycosylation processes

• Exhibits slight esterase activity

• Associates with the monocyte-macrophage system in tissues and body fluids

• Enhances the activity of immunoagents

• Has been implicated in various pathological conditions, including amyloidosis type 8 (AMYL8)

Recent research has revealed LYZ's importance in cancer biology, with studies showing its aberrant expression in solid tumors like hepatocellular carcinoma and its potential as a prognostic biomarker .

What types of LYZ antibodies are available for research?

Several types of LYZ antibodies are available for research applications:

Researchers can choose between unconjugated antibodies or those conjugated with fluorescent labels (e.g., FITC) depending on their specific application needs . The selection should be based on the target species, required applications, and experimental design.

What are the common applications for LYZ antibodies?

LYZ antibodies find utility across multiple experimental techniques:

• Western Blotting (WB): For protein detection and quantification with recommended dilutions typically between 1:500-1:2000 or 1:30000-1:120000 depending on the specific antibody

• Immunohistochemistry (IHC): For tissue localization studies, with dilutions ranging from 1:200-1:800 to 1:1000-1:10000

• Immunocytochemistry/Immunofluorescence (ICC/IF): For cellular localization, typically at 1:50-1:200 or 1:200-1:2000

• Flow Cytometry (FACS): For intracellular staining, recommended at 1-12 μg/mL

• ELISA: For quantitative measurement of LYZ in solution

• Cytometry by Time of Flight (CyTOF): For high-parameter single-cell analysis

Recent publications have demonstrated successful application of LYZ antibodies in cancer research, particularly in studies examining the role of LYZ in hepatocellular carcinoma progression and metastasis .

What species reactivity do LYZ antibodies typically have?

LYZ antibodies show varying reactivity across species:

When selecting an antibody, researchers should verify that the antibody has been validated in their species of interest and for their specific application. Cross-reactivity information is typically provided in product datasheets .

What is the difference between monoclonal and polyclonal LYZ antibodies?

The choice between monoclonal and polyclonal antibodies has significant implications for experimental outcomes:

Monoclonal LYZ Antibodies:

• Recognize a single epitope on the LYZ protein

• Provide higher specificity and lower background

• Ensure consistent lot-to-lot reproducibility

• Often used for specific applications like flow cytometry where precise targeting is required

• Examples include the LZ598-10G9 clone, which recognizes intracellular lysozyme and is used as a marker for lineage diagnosis of acute leukemias

Polyclonal LYZ Antibodies:

• Recognize multiple epitopes on the LYZ protein

• Often yield stronger signals due to multiple binding sites

• May provide better detection in samples where the protein is denatured or partially degraded

• Show broader reactivity across species

• Examples include antibody 15013-1-AP, which has been validated in multiple applications across human, mouse, and rat samples

The choice depends on the specific research question, required sensitivity, and experimental conditions.

What are the optimal dilutions for different applications of LYZ antibodies?

Optimal dilutions vary by application and specific antibody:

Researchers should note that these are recommended starting points, and optimization is often required for specific experimental conditions. As stated in product documentation: "It is recommended that this reagent should be titrated in each testing system to obtain optimal results" .

How can I validate the specificity of a LYZ antibody?

Validating antibody specificity is critical for ensuring reliable results:

• Positive Controls: Use samples known to express LYZ, such as:

  • THP-1 cells

  • HL-60 cells

  • RAW 264.7 cells

  • Mouse lung tissue

  • Human spleen tissue

• Western Blot Analysis: Look for bands at the expected molecular weight (15-17 kDa). Note that the calculated MW is 17 kDa, but the observed MW is often 15 kDa .

• Knockdown/Knockout Validation: Compare antibody staining in wild-type versus LYZ-knockdown or knockout samples.

• Peptide Competition: Pre-incubate the antibody with the immunizing peptide before application to samples. A specific antibody will show diminished or eliminated staining.

• Multiple Antibody Comparison: Use multiple antibodies targeting different epitopes of LYZ to confirm consistent localization and expression patterns.

• Cross-Reactivity Testing: Test the antibody on samples from non-target species to confirm specificity claims.

What are the implications of LYZ detection in tumor research?

Recent studies have revealed important implications for LYZ in cancer biology:

• Prognostic Biomarker: High LYZ abundance in hepatocellular carcinoma (HCC) tissues has been found to predict poor prognosis in patients .

• Subtype Characterization: LYZ has shown opposite expression patterns between tumor and paracancerous tissues in different subtypes of HCC .

• Therapeutic Target: Targeting LYZ has been shown to inhibit HCC growth in both subcutaneous and orthotopic xenograft tumor models, suggesting its potential as a therapeutic target .

• Mechanism of Action: Mechanistically, LYZ has been shown to promote HCC cell proliferation and migration in both autocrine and paracrine manners, independent of its muramidase activity, via cell surface GRP78 .

• Regulation: LYZ expression in poorly differentiated HCC cells appears to be regulated by STAT3 activation .

These findings highlight the potential of LYZ as both a biomarker and therapeutic target for aggressive phenotypes of HCC.

How can I troubleshoot inconsistent results with LYZ antibodies?

When encountering inconsistent results with LYZ antibodies, consider these methodological solutions:

• Antibody Concentration: Titrate the antibody to determine optimal concentration. Different applications require different dilutions (see section 2.3).

• Antigen Retrieval for IHC:

  • Try different retrieval methods: "Suggested antigen retrieval with TE buffer pH 9.0; alternatively, antigen retrieval may be performed with citrate buffer pH 6.0" .

  • Optimize retrieval time and temperature.

• Sample Preparation:

  • For intracellular staining in flow cytometry, ensure proper fixation and permeabilization .

  • For Western blotting, verify complete protein denaturation and appropriate gel percentage for optimal separation of the 15-17 kDa protein.

• Storage and Handling:

  • Store antibodies at -20°C for long-term stability .

  • Avoid repeated freeze/thaw cycles by aliquoting .

  • Note storage buffer composition (e.g., "PBS with 0.02% sodium azide and 50% glycerol pH 7.3" ).

• Positive Controls: Include known positive samples (THP-1 cells, mouse lung tissue, human spleen tissue, or HL-60 cells) .

• Batch Variation: When possible, complete experimental series with the same lot of antibody.

What is known about LYZ's role in cancer and other diseases?

Research has revealed multiple roles for LYZ in disease processes:

• Cancer Biology:

  • Aberrant LYZ expression has been observed in solid tumors beyond its known presence in myeloid and leukemic cells .

  • In HCC, LYZ promotes tumor cell proliferation and migration independent of its enzymatic activity .

  • LYZ acts through cell surface GRP78 to activate protumoral signaling pathways .

  • High LYZ abundance correlates with poor prognosis in HCC patients .

• Leukemia:

  • Elevated levels of LYZ in serum and urine are observed in monocytic and monomyelocytic leukemia .

  • LYZ serves as a biomarker for monocytic/monomyelocytic leukemia and related kidney injury .

• Amyloidosis:

  • Defects in LYZ are a cause of amyloidosis type 8 (AMYL8) .

These findings suggest that targeting LYZ could be a therapeutic strategy for specific cancer subtypes, particularly those showing aberrant LYZ expression.

What are the best practices for multiplexing LYZ antibodies with other markers?

For successful multiplexing experiments with LYZ antibodies:

• Antibody Selection:

  • Choose antibodies raised in different host species to avoid cross-reactivity

  • Select antibodies with non-overlapping emission spectra if using fluorescent detection

  • Verify that fixation and permeabilization conditions are compatible for all targets

• Sequential Staining:

  • Consider sequential rather than simultaneous staining if cross-reactivity is a concern

  • Block between staining steps to minimize non-specific binding

• Controls:

  • Include single-stained controls for each antibody

  • Use fluorescence minus one (FMO) controls when establishing flow cytometry panels

  • Include appropriate isotype controls (e.g., IgG1 for mouse monoclonal antibodies )

• Optimization:

  • Titrate each antibody individually before combining

  • Test for antigenic masking when antibodies target proteins in close proximity

• Technical Considerations:

  • For flow cytometry, ensure proper compensation when using multiple fluorophores

  • For immunofluorescence, be aware of autofluorescence, particularly in tissues like lung that naturally express high levels of LYZ

How do different cell and tissue types express LYZ?

Understanding the cellular and tissue distribution of LYZ is important for experimental design:

This tissue distribution information is valuable for selecting appropriate positive controls and understanding the physiological context of LYZ expression.

How should LYZ antibodies be stored and handled?

Proper storage and handling are essential for maintaining antibody performance:

• Storage Temperature:

  • Store at -20°C for long-term stability

  • Antibodies are typically stable for one year after shipment when properly stored

• Buffer Composition:

  • Most LYZ antibodies are provided in PBS with additives like:

    • 0.02% sodium azide

    • 50% glycerol (pH 7.3)

    • Some may contain 0.05% Proclin-300 and 0.05% BSA

• Aliquoting:

  • Divide into small aliquots to avoid repeated freeze/thaw cycles

  • For some formulations, "Aliquoting is unnecessary for -20°C storage" for small (20μL) sizes containing 0.1% BSA

• Working Solutions:

  • Dilute in appropriate buffer immediately before use

  • Do not store diluted antibody for extended periods

• Safety Considerations:

  • Note that some preparations contain sodium azide, which is toxic

  • Follow safety guidelines for handling biohazardous materials

Proper storage and handling ensure optimal antibody performance and reproducible results across experiments.

What key factors affect the reactivity and sensitivity of LYZ antibodies?

Several factors influence antibody performance in experimental settings:

• Epitope Accessibility:

  • The lysozyme sequence targeted by the antibody affects its performance in different applications

  • For example, antibodies targeting amino acids 1-100 versus C-terminal regions (AA 106-141) may perform differently depending on protein folding and interaction with other molecules

• Fixation Methods:

  • For IHC and ICC, fixation can significantly impact epitope availability

  • Some antibodies perform better with specific antigen retrieval methods:

    • TE buffer pH 9.0 versus citrate buffer pH 6.0

• Protein Conformation:

  • Native versus denatured protein recognition varies between antibodies

  • For applications requiring detection of native protein (e.g., flow cytometry), select antibodies validated for this purpose

• Sample Type:

  • Performance may vary between fresh, frozen, or fixed samples

  • Some antibodies are specifically validated for formalin-fixed paraffin-embedded (FFPE) tissues

• Dilution Optimization:

  • Optimal dilution ranges vary widely between antibodies and applications

  • For example, WB dilutions range from 1:500 to 1:120000 depending on the specific antibody